Global Biliary Tumor Market

Global Biliary Tumor Market Size Insights Forecasts to 2035

• The Global Biliary Tumor Market Size Was valued at USD 0.74 Billion in 2024
• The Global Biliary Tumor Market Size is Expected to Grow at a CAGR of around 6.57% from 2025 to 2035
• The Worldwide Biliary Tumor Market Size is Expected to Reach USD 1.49 Billion by 2035
• Asia Pacific is expected to grow the fastest during the forecast period.

According to a research report published by Decisions Advisors and Consulting, The Global Biliary Tumor Market Size Was Worth Around USD 0.74 Billion In 2024 And Is Predicted To Grow To Around USD 1.49 Billion By 2035 With A Compound Annual Growth Rate (CAGR) Of 6.57% From 2025 To 2035. The global biliary tumor market shows strong growth potential because of increasing disease cases and the development of precision and targeted therapies and advanced diagnostic methods and immuno-oncology research and personalized treatment approaches which will drive market expansion until 2030 and beyond.

 

Market Overview

The global biliary tumor market refers to the worldwide industry dedicated to diagnosing and treating bile duct tumors through its various treatment methods and diagnostic tools and its supportive care technologies which help improve patient health results. Additionally, the biliary tumor market provides multiple paths for business development because new diagnostic methods and treatment technologies are entering the market. The development of new targeted therapies and immunotherapies creates a major business opportunity because these treatments enable doctors to provide better individualized care to their patients. Research into the molecular and genetic basis of biliary tumors has reached a stage where scientists can develop treatments that specifically attack cancer cells while leaving normal cells untouched. The personalized treatment method boosts treatment success rates while decreasing negative effects for patients, which creates a new market growth opportunity.

 

Report Coverage

This research report categorizes the biliary tumor market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the biliary tumor market. Recent market developments and competitive strategies such as expansion, type launch, development, partnership, merger, and acquisition, have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the biliary tumor market. 

 

Driving Factors

The biliary tumor market experiences its main growth because researchers now dedicate more funding toward developing new cancer treatment methods. According to the American Cancer Society, around 31% of new cancer cases in the U.S. are related to preventable risk factors such as smoking and obesity. The pharmaceutical industry now directs its research efforts toward creating targeted therapies and immunotherapies that treat biliary tumors. The growing elderly population creates a need for efficient cancer treatment solutions because this age group faces higher cancer risks. The global market for biliary cancer therapies is projected to grow at a CAGR of approximately 7.5% from 2023 to 2030, according to Verified Market Reports.

 

Restraining Factors

The biliary tumor market needs to solve its current challenges to achieve sustainable development. The main obstacle which needs to be overcome exists because of intricate treatment methods. The limited occurrence of biliary tumors results in healthcare professionals having inadequate experience which causes them to follow different methods of treatment. The existing treatment methods which healthcare professionals use to treat patients create inconsistencies that lead to negative effects on patient outcomes while making it harder to establish clinical guidelines.

 

Market Segmentation

The biliary tumor market share is classified into type and end user.

 

• The treatment segment dominated the market in 2024, approximately 50% and is projected to grow at a substantial CAGR during the forecast period.

Based on the type, the biliary tumor market is divided into treatment (chemotherapy, immunotherapy, targeted therapy, locoregional therapy), and diagnostics. Among these, the treatment segment dominated the market in 2024, approximately 50% and is projected to grow at a substantial CAGR during the forecast period. The research study traces its growth pattern through its development process which establishes biomarker discovery as its primary research focus. The treatment foundation consists of gemcitabine-cisplatin as the main therapy while immunotherapy shows the fastest growth among different treatment areas due to new combination therapies which are changing first-line treatment protocols. The revenue per patient from targeted therapy reaches high levels however its application remains limited because biomarkers occur at low frequencies. Locoregional treatments including Y-90 radioembolization and SBRT have been applied to treat intrahepatic tumors which cannot be surgically removed while TheraSphere usage has increased by 12 percent each year.

• The hospitals segment accounted for the largest share in 2024, approximately 43% and is anticipated to grow at a significant CAGR during the forecast period.

Based on the end user, the biliary tumor market is divided into hospitals, specialty clinics, diagnostics centers, and others. Among these, the hospitals segment accounted for the largest share in 2024, approximately 43% and is anticipated to grow at a significant CAGR during the forecast period. The facilities possess complete infrastructure which enables them to handle complicated biliary tumor procedures. These facilities possess advanced diagnostic equipment and treatment technologies which allow them to deliver complete patient care starting from initial diagnosis until the patient's recovery. The rising occurrence of biliary tumors leads hospitals to acquire advanced medical equipment and hire dedicated specialists which enhances their market presence.

 

Regional Segment Analysis of the Biliary Tumor Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

 

North America is anticipated to hold the largest share of the biliary tumor market over the predicted timeframe.

North America is anticipated to hold the largest share of the biliary tumor market over the predicted timeframe. The United States represents 85 percent of total regional healthcare expenditures because non-alcoholic steatohepatitis and obesity rates continue to rise. The durvalumab treatment cohort only became available to Canada at the end of 2024 while Mexico restricts first-line immunotherapy access to patients who have private insurance.

 

Asia Pacific is expected to grow at a rapid CAGR in the biliary tumor market during the forecast period. Thailand maintains its position as the worldwide center because liver-fluke infection rates exceed 85 cases per 100000 people. The rising urban incidence in China results from increased hepatitis B and aflatoxin exposure. Japan provides financial support through reimbursement while its PMDA process delivers fast drug approval which enables quicker access to new treatments. The South Korean NHIS system included futibatinib in 2025 which resulted in better treatment access for FGFR2-positive patients.

 

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the biliary tumor market, along with a comparative evaluation primarily based on their type of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes type development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

 

List of Key Companies

• Roche Holding AG
• Pfizer Inc.
• Novartis AG
• Bristol-Myers Squibb Company
• Merck & Co., Inc.
• Eli Lilly and Company
• AstraZeneca PLC
• Johnson & Johnson
• Sanofi S.A.
• GlaxoSmithKline plc
• Others

 

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

 

Recent Development

 

• In November 2024, the FDA cleared zanidatamab-gkkz (Ziihera) for previously untreated HER2-positive biliary tract cancer, based on a 41.3% response rate and a median overall survival of 12.5 months.

 

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Decisions Advisors has segmented the biliary tumor market based on the below-mentioned segments: 

 

Global Biliary Tumor Market, By Type

• Treatment
• Chemotherapy
• Immunotherapy
• Targeted Therapy
• Locoregional Therapy
• Diagnostics

 

Global Biliary Tumor Market, By End User

• Hospitals
• Specialty Clinics
• Diagnostics Centers
• Others

 

Global Biliary Tumor Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  •  South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa

 

Frequently Asked Questions (FAQ)

 

Q1. What macro factors are accelerating the global biliary tumor market?

A: The market expands due to rising incidence, precision oncology breakthroughs, increased R&D investment, advanced diagnostics, and supportive reimbursement, collectively accelerating adoption of targeted biliary tumor therapies worldwide across global systems.

 

Q2. Why does the treatment segment lead the biliary tumor market?

A: Treatment leads because combination chemotherapy standards, rapidly evolving immunotherapy, and biomarker-driven targeted agents deliver higher clinical value, improved survival expectations, and strong provider preference within oncology care pathways globally today.

 

Q3. Why are hospitals the primary end users in biliary tumor care?

A: Hospitals dominate as comprehensive centers integrating imaging, surgery, oncology, and supportive care, reflecting burden trends highlighted by the American Cancer Society and driving centralized biliary tumor management worldwide through teams.

 

Q4. How do regional dynamics shape biliary tumor market growth?

A: North America maintains leadership through high spending and rapid innovation, while Asia-Pacific accelerates via rising incidence, regulatory agility, and reimbursement expansion, creating strong regional demand for advanced biliary tumor solutions.